WEKO3
アイテム
Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study
http://hdl.handle.net/10129/0002000932
http://hdl.handle.net/10129/0002000932ac37aedd-df13-488a-a094-a26d557c472d
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
本文 (1.1 MB)
|
.png)
|
|
|
内容要旨 (194 KB)
|
|
|
|
審査要旨 (130 KB)
|
|
| Item type | リポジトリ登録用アイテムタイプ（シンプル）(1) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-06-16 | |||||||||
| タイトル | ||||||||||
| タイトル | Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study | |||||||||
| 言語 | en | |||||||||
| 言語 | ||||||||||
| 言語 | eng | |||||||||
| 資源タイプ | ||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||||
| 資源タイプ | doctoral thesis | |||||||||
| アクセス権 | ||||||||||
| アクセス権 | open access | |||||||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||||
| 著者 |
福島, 高志
× 福島, 高志
|
|||||||||
| 抄録 | ||||||||||
| 内容記述タイプ | Abstract | |||||||||
| 内容記述 | Small-cell lung cancer (SCLC) is a highly malignant tumor, and no standard third-line therapy has been established. The present study retrospectively analyzed the efficacy and safety of platinum‑based regimens in patients with third-line SCLC who received third-line chemotherapy. The association of regimen type with overall survival (OS) or time to treatment failure (TTF) was evaluated using the Cox hazard proportional method, including well known covariates affecting the prognosis of SCLC. TTF and OS analyses were conducted using the Kaplan-Meier method. The data cutoff date was June 30, 2020. As a result, from January 2015 to August 2019, 111 patients were diagnosed with SCLC, and 37 received third-line chemotherapy. Subsequently, 15 patients received a platinum-doublet regimen, and 22 patients received a single-agent regimen. Only the type of regimen was significantly associated with TTF in univariate analysis (odds ratio, 0.44; 95% confidence interval, 0.20-0.95; P=0.03). There were no significant factors associated with OS. The median TTF of patients receiving a platinum-doublet regimen and those receiving a single-agent regimen were 3.9 and 2.3 months, respectively (P=0.03). The overall response rates of the platinum-doublet and single-agent regimens were 20.0 and 4.5%, respectively. Similarly, the disease control rates were 73.3 and 36.4% for platinum-doublet and single-agent regimens, respectively. There was a tendency for adverse events (AEs) with any grade to occur more often in platinum-based regimens compared with in single-agent regimens. Severe AEs of grade 3 or higher were observed more often in the platinum-based regimen, especially in myelosuppression. In conclusion, the present study demonstrated the feasibility and safety of platinum-doublet regimens in patients with SCLC in a third-line setting (Registration no. 2020-048. Date of registration, June 5, 2020). | |||||||||
| 言語 | en | |||||||||
| 内容記述 | ||||||||||
| 内容記述タイプ | Other | |||||||||
| 内容記述 | Authors: Takashi Fukushima, Tomonori Makiguchi, Yusuke Tanaka, Kei Chubachi, Mina Ishidoya, Sachio Suzuki, Hisashi Tanaka, Kageaki Taima, Yukihiro Hasegawa, Koichi Okudera, Sadatomo Tasaka Published online on: September 1, 2022 Article Number: 368 Copyright: © Fukushima et al. This is an open access article distributed under the terms of Creative Commons Attribution License. |
|||||||||
| 言語 | en | |||||||||
| 書誌情報 |
en : ONCOLOGY LETTERS 巻 24, 号 4, 発行日 2022-09-01 |
|||||||||
| ISSN | ||||||||||
| 収録物識別子タイプ | EISSN | |||||||||
| 収録物識別子 | 1792-1082 | |||||||||
| DOI | ||||||||||
| 関連タイプ | isIdenticalTo | |||||||||
| 識別子タイプ | URI | |||||||||
| 関連識別子 | https://www.spandidos-publications.com/10.3892/ol.2022.13488 | |||||||||
| 権利情報 | ||||||||||
| 言語 | en | |||||||||
| 権利情報 | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja | |||||||||
| 出版タイプ | ||||||||||
| 出版タイプ | VoR | |||||||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||||
| 出版者 | ||||||||||
| 出版者 | Spandidos Publications | |||||||||
| 言語 | en | |||||||||
| 学位名 | ||||||||||
| 言語 | ja | |||||||||
| 学位名 | 博士（医学） | |||||||||
| 学位授与機関 | ||||||||||
| 言語 | ja | |||||||||
| 学位授与機関名 | 弘前大学 | |||||||||
| 学位授与年月日 | ||||||||||
| 学位授与年月日 | 2025-03-24 | |||||||||
| 学位授与番号 | ||||||||||
| 学位授与番号 | 甲第2316号 | |||||||||
